SCHEMBL3377472

SCHEMBL3377472

CN(C)CC(=O)c1ccc(C(N)=O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.61
KDM4E B2RXH2 2/20 0.61
USP2 O75604 1/20 0.61
PARP10 Q53GL7 6/20 0.46
PARP4 Q9UKK3 2/20 0.45
PARP1 P09874 2/20 0.45
CA2 P00918 2/20 0.45
CA1 P00915 1/20 0.45
PARP2 Q9UGN5 1/20 0.45
KMT2A Q03164 1/20 0.43
PARP15 Q460N3 1/20 0.43
PARP14 Q460N5 1/20 0.43
PARP16 Q8N5Y8 1/20 0.43
PARP11 Q9NR21 1/20 0.43
MAPT P10636 3/20 0.43
POLB P06746 2/20 0.43
TSHR P16473 2/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C19 P33261 1/20 0.43
RECQL P46063 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3377479 0.83 ALDH1A1 (0.61) ALDH1A1KDM4EUSP2KMT2AMAPT
SCHEMBL28657721 0.81 ALDH1A1 (0.63) ALDH1A1KDM4EUSP2MAPTPOLB
SCHEMBL13917786 0.80 GSR (0.62) PARP10KMT2AGSRTHRATHRB
Terephthalamide SCHEMBL27683041 0.79 PARP10 (0.58) ALDH1A1PARP10PARP4PARP1CA2
SCHEMBL23554948 0.79 ALDH1A1 (0.61) ALDH1A1KDM4EUSP2CA2CA1
SCHEMBL1241306 0.79 ALDH1A1 (0.61) ALDH1A1KDM4EUSP2CA2CA1
SCHEMBL8132385 0.79 ALDH1A1 (0.61) ALDH1A1KDM4EUSP2KMT2AMAPT
SCHEMBL5720470 0.79 ALDH1A1 (0.61) ALDH1A1KDM4EUSP2CA2CA1
SCHEMBL182321 0.78 ALDH1A1 (0.78) ALDH1A1KDM4EUSP2KMT2AMAPT
Hydrochloric Acid SCHEMBL11391547 0.78 ALDH1A1 (0.59) ALDH1A1KDM4EUSP2CA2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354444-B2 Substituted pyrrolidine-2-carboxamides HOFFMANN-LA ROCHE INC. (US) 2013-01-15 US claimed
EP-2340021-B1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES HOFFMANN LA ROCHE (CH) 2012-11-07 EP claimed
US-20100152190-A1 Substituted Pyrrolidine-2-Carboxamides F. HOFFMANN-LA ROCHE AG (CH) 2010-06-17 US claimed
WO-2010031713-A1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2010-03-25 WO claimed
US-20100075948-A1 Substituted Pyrrolidine-2-Carboxamides DING QINGJIE 2010-03-25 US claimed
EP-2534132-B1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES HOFFMANN LA ROCHE (CH) 2017-04-26 EP disclosed
CN-102159207-B Substituted pyrrolidine-2-carboxamides HOFFMANN LA ROCHE 2015-02-04 CN disclosed
US-8354444-B2 Substituted pyrrolidine-2-carboxamides HOFFMANN-LA ROCHE INC. (US) 2013-01-15 US disclosed
EP-2534132-A1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES F. Hoffmann-La Roche AG (CH) 2012-12-19 EP disclosed
EP-2340021-B1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES HOFFMANN LA ROCHE (CH) 2012-11-07 EP disclosed
US-20100152190-A1 Substituted Pyrrolidine-2-Carboxamides F. HOFFMANN-LA ROCHE AG (CH) 2010-06-17 US disclosed
WO-2010031713-A1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2010-03-25 WO disclosed
US-20100075948-A1 Substituted Pyrrolidine-2-Carboxamides DING QINGJIE 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152190-A1 Substituted Pyrrolidine-2-Carboxamides ARG2, CCNY, PYCR1 ALDH1A1 2027/4885KDM4E 272/4885USP2 2449/4885
US-20100075948-A1 Substituted Pyrrolidine-2-Carboxamides ARG2, CCNY, PYCR1 ALDH1A1 2027/4885KDM4E 272/4885USP2 2449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.